2026-01-28 - Analysis Report
**Financial Report for AbbVie (ABBV)**

**Overview**
AbbVie is a pharmaceutical company that develops and markets various medicines, including treatments for conditions such as arthritis, cancer, and immune system disorders.

**Return Rate Comparison**

* Cumulative return of review stock:  **186.19%**
* Cumulative return of comparison stock (S&P 500, VOO):  **128.51%**
* Divergence (max: 91.90, min: -28.20, current: 54.60, relative divergence: 68.90%)
* Relative divergence indicates that the current position is at the top 68.90% percentile of past data.

**Alpha, Beta Analysis**

| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 35.0% | 23.1% | 26.0% | 1.0 | 162.9B |
| 2017-2019 | 27.0% | 23.1% | 2.0% | 1.1 | 156.5B |
| 2018-2020 | -19.0% | 32.9% | -43.0% | 0.8 | 189.4B |
| 2019-2021 | 77.0% | 32.9% | 13.0% | 0.7 | 239.3B |
| 2020-2022 | 100.0% | 32.9% | 96.0% | 0.6 | 285.6B |
| 2021-2023 | 54.0% | 19.5% | 36.0% | 0.4 | 273.9B |
| 2022-2024 | 33.0% | 19.5% | 4.0% | 0.3 | 314.1B |
| 2023-2025 | 84.0% | 20.4% | 9.0% | 0.3 | 403.8B |

**Recent Stock Price Fluctuations**
* Close: **$223.93**
* Last-market: {'price': 223.93, 'previousClose': 220.77, 'change': 1.43}
* 5-day SMA: **$219.64**
* 20-day SMA: **$222.31**
* 60-day SMA: **$224.91**
The recent stock price has shown a sharp rebound.

**RSI, PPO Index Indicators**
* Market Risk Indicator (MRI): **0.70**
* RSI: **50.00**
* PPO: **0.11**
* Hybrid Signal: **Buy** (Cash 0%)
Risk Level: **Medium** (MRI 0.70)
Recent (20 days) relative divergence change: +**6.50** (improving)
7-day Rank change: -**13** (rank down)
7-day Dynamic Expected Return change: -**11.90** (worsening)

**Expected Return**
* Expected Return (%): **25.30%**
* Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events**

* Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price - MarketBeat
* Is the Options Market Predicting a Spike in AbbVie Stock? - TradingView
* AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Yahoo Finance
* Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Mainta - GuruFocus
* Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum - Finviz
* AbbVie Rose 2% Last Week. Hereâ€™s Why It Could Deliver 14% Upside In 2026 - TIKR.com

**Analyst Opinions**
Analyst Consensus:
- Key: **Buy**
- Mean (1=StrongBuy~5=Sell): **1.93** (~Buy)
- Opinions: **27**
- Target Price (avg/high/low): **245.04** / **289.00** / **184.00**

**Comprehensive Analysis**
The company has shown a significant increase in cumulative return, with a divergence of 54.60% relative to the S&P 500. The Alpha, Beta analysis shows a relatively stable performance over the years. Recent stock price fluctuations have shown a sharp rebound, and the RSI, PPO index indicators suggest a medium risk level. The expected return is estimated to be 25.30% if invested long-term. Recent news articles have shown a mixed reaction, with some analysts issuing pessimistic forecasts and others expressing confidence in the company's performance. Based on the analyst opinions, the consensus is that the company is a buy with a target price of $245.04.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.